Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.


  • An abnormality in lipoprotein metabolism that results in elevations of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), and/or non-high-density lipoprotein cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein cholesterol (HDL-C) levels
  • Increase in serum concentration of TC, LDL, TG or non-HDL-C is equivalent to increased risk for cardiovascular diseases


  • Depends on the type of dyslipidemia
  • Hereditary disorders associated with dyslipidemia include familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
  • Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
01 May 2017
Body mass index (BMI), body fat and waist circumference are highly correlated, and all show an association with aggressive prostate cancer, according to a study.
21 Jun 2017
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
Roshini Claire Anthony, 20 Jun 2017

Adults with type 1 diabetes (T1D) who are prescribed metformin experience reductions in atherosclerosis progression and LDL cholesterol, according to results of the REMOVAL* study. However, the impact of metformin on glycaemic control in these patients is limited.

Christina Lau, 21 Jun 2017

Denosumab brings greater gains in spine and hip bone mineral density (BMD) than risedronate in glucocorticoid-treated patients at risk of osteoporotic fracture, according to results of a phase III study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 in Madrid, Spain.